Antibiotic combinations are increasingly used to combat bacterial infections. Multidrug therapies are a particularly important treatment option for E. faecalis, an opportunistic pathogen that contributes to high-inoculum infections such as infective endocarditis. While numerous synergistic drug combinations for E. faecalis have been identified, much less is known about how different combinations impact the rate of resistance evolution. In this work, we use high-throughput laboratory evolution experiments to quantify adaptation in growth rate and drug resistance of E. faecalis exposed to drug combinations exhibiting different classes of interactions, ranging from synergistic to suppressive. We identify a wide range of evolutionary behavior, including both increased and decreased rates of growth adaptation, depending on the specific interplay between drug interaction and drug resistance profiles. 
INTRODUCTION
The rapid rise of antibiotic resistance poses a growing threat to public health (1, 2) .
The discovery of new antimicrobial agents is a long and difficult process, underscoring the need for new approaches that optimize the use of currently available drugs. In recent years, significant efforts have been devoted to designing evolutionarily sound strategies that balance short-term drug efficacy with the long-term potential to develop resistance. These approaches describe a number of different factors that could modulate resistance evolution, including interactions between bacterial cells (3, 4, 5, 6, 7, 8) , synergy with the immune system (9), spatial heterogeneity (10, 11, 12, 13, 14, 15) , epistasis between resistance mutations (16, 17) , precise temporal scheduling (18, 19, 20, 21) , and statistical correlations between resistance profiles for different drugs (22, 23, 24, 25, 26, 27, 28, 29, 30, 31) .
Drug combinations are an especially promising and widely used strategy for slow-ing resistance (32) . From a clinical perspective, synergistic interactions-where the combined effect of the drugs is greater than expected based on the effects of the drugs alone (33)-have long been considered desirable because they provide strong antimicrobial effects at reduced concentrations. By contrast, drug pairs that interact antagonistically-effectively weakening one another in combination-have been traditionally avoided. Work over the last decade has challenged this conventional wisdom by demonstrating that synergistic interactions have a potentially serious drawback: they may accelerate the evolution of resistance (34, 35, 36) . Similarly, antagonistic interactions can slow or even reverse the evolution of resistance (37) . These results indicate that drug interactions underlie a natural trade-off between short-term efficacy and long-term evolutionary potential (38) . In addition, recent work has shown that cross-resistance (or collateral sensitivity) between drugs in a combination may also significantly modulate resistance evolution (27, 39, 26) . As a whole, these studies show that drug interactions and collateral effects may combine in complex ways to influence evolution of resistance in multi-drug environments.
Combination therapies are an important tool for treating enterococcal infections, which lead to significant morbidity and mortality (40, 41, 42, 43) . E. faecalis is among the most commonly isolated enterococcal species and underlies a host of human infections, including infective endocarditis, infections of the urinary tract or blood stream, and infections related to surgical devices and medical implants. Multiple combination therapies have been proposed or are currently in use for E. faecalis infections (44, 45, 40) . While synergistic combinations are the standard-particularly for high inoculum infections-relatively little is known about how different combinations affect the potential for, and rate of, resistance evolution.
To address these questions, we use large scale laboratory evolution to measure growth adaptation and phenotypic resistance in populations of E. faecalis exposed to four different two-drug combinations over multiple days. The drug pairs include several clinically relevant combinations-for example, two β-lactams or a β-lactam and an amimoglycoside-and exhibit a range of interactions, from synergistic to strongly antagonistic (suppressive). Our results reveal rich and at times surprising evolutionary behavior. In all cases, we find that different dosing combinations lead to significantly different rates of growth adaptation, even when the level of inhibition is constant. In some cases, differences in growth adaptation appear to be driven by selection for distinct cross-resistance profiles, while in other cases, strong interactions between the drugs lead to different adaption rates but highly similar profiles. We show that qualitative features of these evolutionary trajectories can be understood using simple rescaling arguments that link resistance profiles in evolving populations to geometric transformations of the two-drug response surface in ancestral cells. Our results represent a quantitative case study in the evolution of multidrug resistance in an opportunistic pathogen and highlight both potential limitations and unappreciated evolutionary benefits of different drug combinations.
RESULTS

Selection of antibiotic pairs with different interactions.
We first set out to identify a set of two-drug combinations that include a range of interaction types: synergistic, antagonistic, and suppressive (i.e. strongly antagonistic so that the effect of the combination is less than that of one of the drugs alone). To do so, we measured the per capita growth rate of E. faecalis V583 populations in liquid cultures exposed to multiple drug pairs at 90-100 dosage combinations per pair. We estimated per capita growth rate in early exponential phase from optical density (OD) time series acquired using an automated microplate reader and plate stacker (Methods). The type of interaction for each drug pair is defined by the shape of the contours of constant growth ("isoboles") describing the growth response surface g (D 1 , D 2 ), where D i is the concentration of drug i . Linear contours of constant growth represent additive (noninteracting) pairs-for example, the effect of one unit of drug 1 or drug 2 alone is the same as that of a combination with half a unit of each drug. Deviations from additivity include synergy (antagonism), which corresponds to contours with increased concavity (convexity), rendering an equal mixture of the two drugs more (less) effective than in the non-interacting scenario. While other metrics exist for quantifying drug interactions (see, for example, (33)), we choose this Loewe null model (46) because, as we will see, its simple geometric interpretation provides useful intuition for interpreting evolutionary trajectories (37, 35) . Based on these interaction measures and with an eye towards choosing clinically relevant combinations when possible, we decided to focus on 4 drug combinations: ceftriaxone (CRO) and ampicillin (AMP); ampicillin and streptomycin (STR); ceftriaxone and ciprofloxacin (CIP); and tigecycline (TGC) and ciprofloxacin. We describe these combinations in more detail below.
Laboratory evolution across iso-inhibitory dosage combinations. (44, 40) .
As expected, we found that the CRO-AMP combination is strongly synergistic in the ancestral V583 E. faecalis strain (Figure 1a , left panel). We selected four dosage combinations (labeled A-D) along the concave contour of constant inhibition and evolved replicate populations to each condition. Growth curves on day 0, the first day of evolution, show similar levels of inhibition for each combination, but the day 2 curves vary substantially between replicates and between conditions (Figure 1a , right panels).
To quantify growth, we estimated per capita growth rate during the early-exponential phase of growth for each day and each condition using nonlinear least squares fitting to an exponential function ( Figure 1b , left panels; Figure S1 ). In all four conditions, growth increases significantly by day 2, though the rate of adaptation is considerably different across conditions. Notably, day 2 growth rate is higher when both drugs are present We observed qualitatively similar behavior in a combination of a β-lactam and fluoroquinolone (ciprofloxacin). Ciprofloxacin (CIP) is not typically used in the treatment of enterococci, though it has been used with β-lactams in the treatment of enterococcal endocarditis with high-level aminoglycoside resistance (48) . In vitro studies also demonstrate efficacy of ciprofloxacin in multiple combinations against E. faecalis biofilms (49).
We investigated resistance evolution in a combination of CIP with CRO, which is not a As with the AMP-STR combination, we observe slowed growth adaptation in combinations of CRO-CIP relative to that in the component drugs alone (Figure 3b ; Figure S3 ).
Adaptation to CRO alone leads to strong CRO resistance and slight CIP sensitivity (Figure 3c, red) . On the other hand, adaptation to CIP alone leads to CIP resistance along with significant increases in CRO sensitivity (Figure 3c 
DISCUSSION
Using laboratory evolution, we have shown that adaptation of E. faecalis populations to drug combinations can differ substantially from adaptation to the component drugs.
While the evolutionary trajectory of any particular population is difficult to predict, the results as a whole point to simple trends that can be explained with rescaling arguments linking growth of adapted populations to growth of the ancestral population at properly rescaled drug dosages. These arguments show, for example, how identical resistance profiles yield different growth rates for different selecting conditions. The analysis also suggests that, in multiple cases, the profiles selected by different dosage combinations are very nearly growth-optimized linear combinations of the profiles selected by the individual component drugs.
It is important to point out several limitations to our study. First, our goal was not to investigate the specific molecular mechanisms involved in drug adaption, but instead to provide a quantitative picture of resistance evolution that does not require extensive molecular-level knowledge, which many times is not available. However, the richness of the observed phenotypes points to complex and potentially interesting genetic changes that can be partially resolved with modern sequencing technologies.
For example, cross-resistance observed between ceftriaxone and ampicillin may be due to mutations in penicillin-binding proteins, which are common resistance determinants for both drugs (47) . We also note that our experiments were performed just below the minimum inhibitory drug concentrations, allowing for slowed but nonzero proliferation. Previous work indicates that drug interactions may modulate evolution in different ways at higher drug concentrations (27) . In addition, our experiments were performed in planktonic populations, while many of the high-inoculum infections requiring combination treatment are likely to involve surface-associated biofilms, where spatial heterogeneity and complex community dynamics can dramatically alter the response to antibiotics. In E. faecalis , for example, population density can significantly modulate growth dynamics (8) , while sub-inhibitory doses of cell wall inhibitors may actually promote biofilm growth (54) . Recent work in other bacterial species also shows that evolutionary adaptation may differ between biofilm and planktonic communities (55, 56) . Investigating adaptation to drug combinations in these different regimes, both at clinically-relevant concentrations and in biofilms, remains an interesting avenue for future work.
There are also several notable technical limitations. It is clear that all growth curves are not purely exponential, and in fact the per capita growth rate can change with time.
Our growth rate estimates should therefore be thought of as an effective growth rate that reduces the population dynamics each day to a single number. Similarly, the rescaling analysis assumes that the drug resistance in the population can be captured by a Most importantly, we stress that our results are based on in vitro laboratory experiments, which provide a well-controlled but potentially artificial-and certainly simplified-environment for evolutionary selection. While in vitro studies form the basis for many pharmacological regimens, the ultimate success or failure of new therapies must be evaluated using in vivo model systems and, ultimately, controlled clinical trials.
We hope the results presented here offer a provocative look at evolution of E. faecalis in multidrug environments, but it is clear that these findings are not directly transferable to the clinic. Our results do include some clinically relevant antibiotic combinations, though we also sought a wide range of drug interaction types, including multiple antagonistic combinations that are unlikely a priori choices for clinical use. It is notable, however, that these non-synergistic combinations often produced considerably slower growth adaptation, consistent with previous results that highlight potential benefits for non-standard combinations (34, 35, 37) .
Finally, our results reveal that simple rescaling arguments-similar to those originally introduced in (35, 37)-can be used to understand many features of evolution in two-drug environments. Extending and formalizing these qualitative findings using stochastic models where fast evolutionary dynamics are coupled to geometric rescaling on adiabatically changing interaction landscapes is an exciting avenue for theoretical work that may provide both general insight as well as specific, experimentally testable predictions for how resistance evolves in multi-drug environments. Control wells containing ancestral cells and BHI medium were included on each plate as a growth control and for background subtraction, respectively. All dilutions and daily transfers were performed inside a ThermoFisher 1300 Series A2 safety cabinet to minimize contamination. Samples from each population were stocked in 15 percent glycerol and stored at -80C. Estimating per capita growth rate and drug response surfaces We estimated per capita growth rate from OD time series by fitting the early exponential phase portion of the background subtracted curves (typically OD<0.4) to an exponential function using nonlinear least squares (MATLAB 7.6.0 curve fitting toolbox, Mathworks).
We normalized all growth rates by the growth rate of ancestral cells in the absence of drugs. We visualized two-drug growth response surfaces by smoothing (2-d cubic spline interpolation) to reduce experimental noise and displaying smoothed surfaces as two-dimensional heat maps. When relevant, growth at unsampled regions of the growth surface was estimated with 2d interpolation. Phenotypic resistance profiling Experiments to estimate the half-maximal inhibitory concentration (IC 50 ) for each population were performed in replicates of 4-8 in 96-well plates. Prior to IC 50 testing, frozen stocks for each population were swabbed and grown overnight in drug-free medium. These overnight cultures were then diluted 100X into new plates containing fresh media and a gradient of 6-14 drug concentrations.
After 20 hours of growth the optical density at 600 nm (OD600) was again measured and used to create a dose response curve. To quantify drug resistance, the resulting dose response curve was fit to a Hill-like function f (x ) = (1 + (x /K ) h ) −1 using nonlinear least squares fitting, where K is the half-maximal inhibitory concentration (I C 50 ) and h is a Hill coefficient describing the steepness of the dose-response relationship. 
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